Michal J Besser

Summary

Country: Israel

Publications

  1. doi request reprint Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy
    M J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    Cytotherapy 11:206-17. 2009
  2. pmc Focus on adoptive T cell transfer trials in melanoma
    Liat Hershkovitz
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer 52621, Israel
    Clin Dev Immunol 2010:260267. 2010
  3. ncbi request reprint Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
    Michal J Besser
    Ella Institute of Melanoma, Department of Surgical Oncology, Sheba Medical Center, Ramat Gan, Israel
    Clin Cancer Res 19:4792-800. 2013
  4. doi request reprint Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
    Michal J Besser
    The Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    J Immunother 32:415-23. 2009
  5. doi request reprint Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
    Michal J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    Clin Cancer Res 16:2646-55. 2010
  6. pmc Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack
    Gal Markel
    The Ella Institute of Melanoma, Sheba Cancer Research Centre, Sheba Medical Centre, Tel Hashomer, Israel
    Immunology 126:186-200. 2009
  7. doi request reprint A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study
    Eyal Greenberg
    Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
    Biomarkers 18:502-8. 2013
  8. pmc Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma
    Orit Itzhaki
    Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
    PLoS ONE 8:e57160. 2013
  9. doi request reprint Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy
    Orit Itzhaki
    Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    J Immunother 34:212-20. 2011
  10. pmc Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies
    Michal J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    PLoS ONE 8:e57922. 2013

Collaborators

Detail Information

Publications24

  1. doi request reprint Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy
    M J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    Cytotherapy 11:206-17. 2009
    ..Therefore interleukin-2 (IL-2), a potent T-cell mitogenic cytokine that critically affects the features and effectiveness of T cells, is frequently added to cell culture media...
  2. pmc Focus on adoptive T cell transfer trials in melanoma
    Liat Hershkovitz
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer 52621, Israel
    Clin Dev Immunol 2010:260267. 2010
    ..This paper focuses on the latest progress regarding adoptive T cell transfer, comparing the currently available protocols and discussing their advantages, disadvantages, and implication in the future...
  3. ncbi request reprint Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
    Michal J Besser
    Ella Institute of Melanoma, Department of Surgical Oncology, Sheba Medical Center, Ramat Gan, Israel
    Clin Cancer Res 19:4792-800. 2013
    ..Here, we present the intent-to-treat analysis of TIL ACT and analyze parameters predictive to response as well as the impact of other immunotherapies...
  4. doi request reprint Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
    Michal J Besser
    The Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    J Immunother 32:415-23. 2009
    ..The use of minimally cultured, unselected Young-TIL enables the treatment of most enrolled patients. Although the cohort of Young-TIL patients treated so far is rather small and the follow-up short, the response rate is encouraging...
  5. doi request reprint Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
    Michal J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    Clin Cancer Res 16:2646-55. 2010
    ..The purpose of this study is to explore the efficacy and toxicity of adoptively transferred Young-TIL following lympho-depleting chemotherapy in metastatic melanoma patients, refractory to interleukin-2 and chemotherapy...
  6. pmc Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack
    Gal Markel
    The Ella Institute of Melanoma, Sheba Cancer Research Centre, Sheba Medical Centre, Tel Hashomer, Israel
    Immunology 126:186-200. 2009
    ..Therefore, this work substantiates the melanoma-promoting role of CEACAM1 and marks it as an attractive target for novel immunotherapeutic interventions...
  7. doi request reprint A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study
    Eyal Greenberg
    Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
    Biomarkers 18:502-8. 2013
    ..Quantification of circulating microRNAs (miRNAs) has recently become feasible and reliable, with most efforts focusing on miRNAs overexpressed by cancer cells...
  8. pmc Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma
    Orit Itzhaki
    Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
    PLoS ONE 8:e57160. 2013
    ..Targeting VM, especially in combination with anti-angiogenic strategies, is expected to be synergistic and might yield substantial anti neoplastic effects in a variety of malignancies...
  9. doi request reprint Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy
    Orit Itzhaki
    Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    J Immunother 34:212-20. 2011
    ..In the future this approach may be used also in other types of malignancies...
  10. pmc Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies
    Michal J Besser
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    PLoS ONE 8:e57922. 2013
    ..g. antibodies and specific activation, as well as donor selection according to HLA or CD16 genotypes. This study rationalizes a clinical trial that combines adoptive transfer of highly potent allogeneic NK cells and antibody therapy...
  11. doi request reprint Immunotherapy for the management of advanced melanoma: the next steps
    Dragoslav Zikich
    Ella Institute for Melanoma, Sheba Medical Center, 52621 Ramat Gan, Israel
    Am J Clin Dermatol 14:261-72. 2013
    ..This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma. ..
  12. pmc MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth
    Yael Nemlich
    Ella Institute of Melanoma, Ramat Gan, Israel
    J Clin Invest 123:2703-18. 2013
    ..We further demonstrated that the genes encoding miR-17 and miR-432 are frequently amplified in melanoma and that aberrant hypomethylation of the imprinted DLK1-DIO3 region in chromosome 14 can also drive miR-432 overexpression...
  13. ncbi request reprint CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy
    Sivan Sapoznik
    The Ella Institute for Melanoma Research and Treatment, Cancer Research Center, Sheba Medical Center, 52621 Ramat Gan, Tel Hashomer, Israel
    Cancer Immunol Immunother 61:1833-47. 2012
    ..This approach is complimentary and potentially synergistic with other genetic strategies designed to enhance anti-tumor potency...
  14. doi request reprint Systemic dysregulation of CEACAM1 in melanoma patients
    Gal Markel
    The Ella Institute for Melanoma Research and Treatment, Sheba Cancer Research Center, Sheba Medical Center, 52621 Tel Hashomer, Israel
    Cancer Immunol Immunother 59:215-30. 2010
    ..In conclusion, the systemic dysregulation of CEACAM1 in melanoma patients further denotes the role of CEACAM1 in melanoma and may provide a basis for new tumor monitoring and prognostic platforms...
  15. doi request reprint Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions
    Rona Ortenberg
    Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel
    Mol Cancer Ther 11:1300-10. 2012
    ....
  16. ncbi request reprint Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center
    Michal J Besser
    Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 8:164-8. 2006
    ....
  17. ncbi request reprint Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma
    Gal Markel
    Ella Institute of Melanoma, Sheba Cancer Research Center, Israel
    Anticancer Res 29:145-54. 2009
    ..Advances in tumor-infiltrating lymphocytes (TIL) generation technology and modified clinical protocols recently yielded a 50% response in refractory melanoma patients...
  18. pmc Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms
    Sivan Sapoznik
    Ella Institute for Melanoma, Sheba Medical Center, Ramat Gan 52621, Israel
    Clin Dev Immunol 2012:818214. 2012
    ..This paper combines multi-disciplinary approaches and describes anti-melanoma immunotherapies from molecular, medical, and business angles...
  19. doi request reprint Adoptive T-cell transfer in melanoma
    Orit Itzhaki
    Ella Institute for Melanoma, Sheba Medical Center, 52621 Ramat Gan, Israel
    Immunotherapy 5:79-90. 2013
    ..These approaches opened numerous possibilities to treat cancers other than melanoma. In this article we will summarize the ACT strategies in melanoma, the new developments in this field and combinations with other therapies...
  20. ncbi request reprint Collection of large-scale expanded lymphocyte cultures for adoptive immunotherapy using a COBE Spectra apheresis machine
    Ester Schallmach
    Ella Institute for Treatment and Research of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    J Immunother 31:563-8. 2008
    ..Our results show a high recovery yield (98%+/-15%) and viability (ranged 79% to 99%) of the large-scale expanded lymphocytes. It preserves sterility of the product and is therefore suitable for immunotherapy treatments...
  21. pmc Regulation of cancer aggressive features in melanoma cells by microRNAs
    Eyal Greenberg
    Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel
    PLoS ONE 6:e18936. 2011
    ..Collectively, these findings may prove instrumental for understanding mechanisms of disease and for development of novel therapeutic and staging technologies for melanoma...
  22. pmc Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells
    Gal Markel
    Ella Institute of Melanoma, Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel
    PLoS ONE 4:e5597. 2009
    ..Here we suggest an alternative approach for augmentation of anti tumor effect of allogeneic NK cells, which is founded on profile matching of donor NK lysis receptors (NKLR) phenotype with tumor lysis-ligands...
  23. ncbi request reprint CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases
    Shai Shrot
    Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, 2 Sheba Rd, Tel Hashomer 52621, Israel, Affiliated to Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur Radiol 24:1251-6. 2014
    ..We describe the appearance of a halo sign following treatment of adoptive transfer of autologous tumour-infiltrating lymphocytes (TIL) to melanoma patients with lung metastases...